Related Experiment Video
Updated: Mar 31, 2026
Lipidomics and Transcriptomics in Neurological Diseases
Published on: March 18, 2022
Identification and Analysis of Remimazolam's Potential Therapeutic Mechanisms in Murine Sepsis-Associated
Jin Zhou1, Wen Hu1, Yushan Luo2
1Department of Anesthesiology, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, People's Republic of China.
Background:
Sepsis-associated encephalopathy (SAE) is a common complication of sepsis, marked by neuroinflammation and cognitive impairment. Remimazolam (Rem), a novel ultra-short-acting benzodiazepine, exhibits potential anti-inflammatory and neuroprotective effects; however, its molecular mechanisms in SAE remain poorly understood.
Methods:
Male mice were randomly assigned to three groups: SHAM (Con, n=6), Sepsis (CLP, n=6), and remimazolam-treated Sepsis (Rem, n=6). Hippocampal tissues were collected for RNA sequencing. Differential expression analysis was performed to identify genes modulated by Rem treatment. To further screen candidate genes, weighted gene co-expression network analysis (WGCNA) and protein-protein interaction (PPI) networks were utilized, and functional enrichment was assessed through gene set enrichment analysis (GSEA). Immune microenvironment alterations were compared across groups, and potential therapeutic compounds targeting hub genes were predicted using public drug-gene interaction databases. Hub gene expression was validated at both mRNA (qRT-PCR) and protein levels.
Results:
RNA-seq identified 3397 and 914 differentially expressed genes (DEGs) in the Sepsis (CLP vs Con) and remimazolam-treated (Rem vs CLP) groups, respectively. A total of 647 key DEGs with opposing expression trends were screened. Through WGCNA and PPI analysis, five hub genes-ICAM1, Tlr2, Cd274, FOS, and SOCS3-were identified. Pathways related to inflammatory response, IL6/JAK/STAT3 signaling, and TNFα/NF-κB signaling were significantly enriched with these genes, suggesting their potential role in the pathogenesis of SAE. Among the twenty-one candidate drugs predicted to target these hub genes, AVELUMAB-CD274 and LIFITEGRAST-ICAM1 exhibited high binding affinity. The expressions of ICAM1, Tlr2, Cd274, and SOCS3 were further validated at both mRNA (qRT-PCR) and protein levels, corroborating the transcriptomic findings.
Conclusion:
This study reveals that ICAM1, Tlr2, Cd274, and SOCS3 are key molecular correlates of remimazolam treatment in a murine SAE model. Our transcriptomic analysis offers insights into the molecular basis of remimazolam's protective effects, highlighting these genes and pathways for future research.
Insights
Remimazolam treatment in sepsis-associated encephalopathy (SAE) identified key genes ICAM1, Tlr2, Cd274, and SOCS3. This research illuminates the molecular mechanisms behind remimazolam
Area of Science:
- Neuroscience
- Pharmacology
- Molecular Biology
Background:
- Sepsis-associated encephalopathy (SAE) is a common complication of sepsis, characterized by neuroinflammation and cognitive impairment.
- Remimazolam, a novel ultra-short-acting benzodiazepine, shows potential anti-inflammatory and neuroprotective effects.
- The precise molecular mechanisms of remimazolam in SAE are not well understood.
Purpose of the Study:
- To investigate the molecular mechanisms of remimazolam in a murine model of sepsis-associated encephalopathy.
- To identify key genes and pathways modulated by remimazolam treatment in SAE.
- To explore potential therapeutic targets for SAE.
Main Methods:
- Utilized RNA sequencing on hippocampal tissues from SHAM, Sepsis (CLP), and remimazolam-treated Sepsis (Rem) groups of male mice.
- Applied weighted gene co-expression network analysis (WGCNA) and protein-protein interaction (PPI) networks to screen candidate genes.
- Performed gene set enrichment analysis (GSEA) for functional enrichment and validated hub gene expression at mRNA and protein levels.
Main Results:
- RNA-seq identified significant differentially expressed genes (DEGs) between groups.
- WGCNA and PPI analysis identified five hub genes: ICAM1, Tlr2, Cd274, FOS, and SOCS3.
- Enriched pathways included inflammatory response, IL6/JAK/STAT3, and TNFα/NF-κB signaling; ICAM1, Tlr2, Cd274, and SOCS3 expression were validated.
Conclusions:
- ICAM1, Tlr2, Cd274, and SOCS3 are identified as key molecular correlates of remimazolam treatment in a murine SAE model.
- Transcriptomic analysis provides insights into the molecular basis of remimazolam's protective effects in SAE.
- These identified genes and pathways warrant further investigation for SAE therapeutic strategies.
More Related Videos
08:47Induction of Experimental Autoimmune Encephalomyelitis in Mice and Evaluation of the Disease-dependent Distribution of Immune Cells in Various Tissues
Published on: May 8, 2016
05:33A Model for Epilepsy of Infectious Etiology using Theiler's Murine Encephalomyelitis Virus
Published on: June 23, 2022